Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Somatostatin Analogs Market will reach USD 12.05 billion by 2032 at a CAGR of 7.1% during the forecast period. The market for somatostatin analogs is dynamic and influenced by several factors that collectively shape its growth prospects for the coming years. These chemical compounds that imitate the effects of naturally occurring somatostatin hormones are vital in treating many endocrinology conditions. The dynamics of the Somatostatin Analogs Market significantly depend on research and development (R&D) activities within this industry. Pharmaceutical manufacturers, as well as researchers, are continually innovating better analog formulations that would improve efficacy, patient compliance, and duration of effect while enhancing these properties. Ongoing clinical trials, advancements in drug delivery systems, and expanding indications contribute to widening treatment options, thereby positively influencing market dynamics in this case.
The exploration for new and more efficient somatostatin analogs also drives industry movements. Technological advancements play a substantial role in determining the market dynamics for these types of drugs by making them much easier to deliver into bodies over long distances or short ones through different routes, such as subcutaneous injections, among others, thus improving patient compliance and comfort. Besides enhancing treatment choices, these medical innovations have helped create an environment where doctors can effectively manage various health problems mainly because they empower clinicians with modern tools and technologies used in managing illnesses more accurately.
Regulation matters, including approval processes, are key considerations that influence market dynamics on somatostatin analogs. Strict regulatory standards ensure the safety and effectiveness of new drugs, while regulatory approvals give credibility to treatments and facilitate access to markets for such products. Pharmaceutical companies use strategies like improved versions of existing drugs or entirely new ones depending on their target market segment. Such companies need a thorough understanding of their product's intended usage and prevailing government regulations since it allows them to strategically navigate through those landscapes so as to bring onto markets new, improved somatostatin analogs, all of which have broader implications industrywide.
Market dynamics are also influenced by competition among pharmaceutical companies and healthcare stakeholders. The companies employ various strategies such as mergers, acquisitions, and collaborations to strengthen their market positions and expand their somatostatin analog portfolios. Economic factors are also critical in the market dynamics of somatostatin analogs. Economic conditions affect the patterns of health care spending that affect how affordable and accessible patients can access treatment for various treatments. Economic downturns may lead to cost-conscious approaches in healthcare, potentially impacting market growth. Consumer demand patterns greatly influence market dynamics. Consumers' rising awareness of endocrine disorders and increased availability of somatostatin analogs encourage patients to seek timely treatment options with efficiency. Factors such as decreased side effects, less frequent dosing regimens preferred by customers or patients, and ease of use are guiding the development efforts toward the production of innovative drug formulations and therapeutic modalities.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Growth Rate | 7.10% (2023-2032) |
Somatostatin Analogs Market Highlights:
Global Somatostatin Analogs Market Overview
The Somatostatin Analogs Market Size was valued at USD 6.5 Billion in 2022. The somatostatin analogs market industry is projected to grow from USD 6.96 Billion in 2023 to USD 12.05 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.10% during the forecast period (2023 - 2032). In the near future, it is anticipated that the prevalence of neuroendocrine tumors (NETs), acromegaly, Cushing syndrome, and other related disorders will quicken the expansion of this market. The market for somatostatin analogs is expanding due to several market drivers, including increasing R&D efforts and the introduction of novel pharmacological regimens.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Somatostatin Analogs Market Trends
- Increase in neuroendocrine tumors is driving the market growth
The market CAGR for somatostatin analogs is anticipated to develop due to the increase in neuroendocrine tumors. Malignancies that begin in specialized neuroendocrine cells are referred to as neuroendocrine tumors. Somatostatin analogs stop the body from making too many hormones. They lessen carcinoid symptoms and slow the formation of neuroendocrine tumors. For instance, a person has a 1 in 55 chance of developing neuroendocrine tumors by age 85, according to Cancer Australia, a national government organization with headquarters in Australia. In 2022, around 5,437 new instances of neuroendocrine tumors were reported in Australia. As a result, the market for somatostatin analogs is expanding as neuroendocrine tumors become more common.
The development of innovative drug therapies is crucial in the somatostatin analog market. Major players in the somatostatin analogs industry are creating cutting-edge drug solutions to improve their market share. For instance, in August 2020, US-based biopharmaceutical company Chiasma Inc. introduced Mycapssa (octreotide) capsules in the country for people with acromegaly. The long-term maintenance of acromegaly in individuals whose first octreotide or lanreotide treatment has been well-tolerated and effective is indicated for Mycapssa, the first oral somatostatin analog. If these treatments are effective and well tolerated by the body, MYCAPSSA can be used instead of injections.
Acromegaly is a disease that manifests as abnormal development on the hands, feet, and face. Somatostatin analogs are a potential treatment option for this condition, brought on by the pituitary gland's excessive synthesis of growth hormone. As a result, the value of the somatostatin (SSA) analogs market is anticipated to rise in the years to come with the rise in the number of acromegaly cases. Acromegaly affects anywhere between 3 and 15 people out of every 100,000.
The existence of favorable government insurance policies and programs for people with rare diseases is a crucial factor in the growth of the industry. The National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences (NCATS), for example, are only two examples of the several government healthcare agencies in the United States and Europe that provide subsidized medications for rare diseases. Both the United States and Europe experience this. Thus, driving the somatostatin analogs market revenue.
Somatostatin Analogs Market Segment Insights
Somatostatin Analogs Type Insights
The somatostatin analogs market segmentation, based on type includes Octreotide, Lanreotide and Pasireotide. The octreotide segment dominated the market. The benefits of octreotide and its numerous therapeutic uses to treat various disorders, such as carcinoid tumors, vasoactive intestinal peptide tumors, and acromegaly, are becoming more widely known, which is the primary reason for the segment's substantial increase. Additionally, it is projected that the increasing popularity of octreotide treatment among medical experts due to its excellent results and increased effectiveness will create attractive opportunities for segment growth.
Somatostatin Analogs Application Insights
The somatostatin analogs market segmentation, based on application, includes Neuroendocrine Tumor (NET), Acromegaly and Others. The acromegaly category generated the most income. Growing public awareness of acromegaly and the availability of efficient treatment options are the main factors propelling the segment's rise. For instance, Acromegaly Awareness Day was conducted in Canada in November 2018 and provided details on the condition, treatment choices, and advantages of each.
Figure 1: Somatostatin Analogs Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Somatostatin Analogs Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American somatostatin analogs market area will dominate this market. It is predicted that the region's main driver for market expansion will be the increase in acromegaly, neuroendocrine tumors, and cancer cases in the United States and Canada. In addition, it is predicted that market growth in the region will be supported over the next years by expanding knowledge of the medicinal benefits of employing somatostatin analogs and their rising use for carcinoid syndrome.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: SOMATOSTATIN ANALOGS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe somatostatin analogs market accounts for the second-largest market share. The growing awareness of and spending on healthcare in the region will ensure that it continues to dominate the industry. The discovery of better medications and the introduction of new businesses have both fueled market expansion. Additionally, the future expansion of the market is anticipated to be due to the presence of an effective healthcare system and rising investment levels. Further, the German somatostatin analogs market held the largest market share, and the UK somatostatin analogs market was the fastest growing market in the European region.
The Asia-Pacific Somatostatin analogs Market is expected to grow at the fastest CAGR from 2023 to 2032. The presence of a sizable pool of patients with hormonal illnesses and the rising population in several of the region's countries are the main drivers of market expansion in the area. Furthermore, an increase in the number of NET diagnoses in nations like India, Japan, and South Korea, along with increased per capita income, is one of the market's key growth drivers. Additionally, it is projected that increased pharmaceutical company spending would open up profitable expansion opportunities in the not-too-distant future. Moreover, China’s somatostatin analogs market held the largest market share, and the Indian somatostatin analogs market was the fastest growing market in the Asia-Pacific region.
Somatostatin Analogs Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the somatostatin analogs market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, somatostatin analogs industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the somatostatin analogs industry to benefit clients and increase the market sector. In recent years, the somatostatin analogs industry has offered some of the most significant advantages to market. Major players in the somatostatin analogs market attempting to increase market demand by investing in research and development operations include Novartis AG (Switzerland), Ipsen Pharma (France), Fresenius Kabi (Germany), Peptron (South Korea), Pfizer Inc. (US), and Teva Pharmaceuticals Inc. (Israel).
Development, production, and marketing of pharmaceutical products and medical equipment are performed by Fresenius Kabi AG (Fresenius Kabi), a fully owned subsidiary of Fresenius SE & Co KGaA. Its product line comprises clinical nutrition products, infusion therapy items, injectable medications, and medical equipment. The company's therapeutic competence includes fluid management, anesthesia, critical illness, malnutrition or malabsorption, diabetes mellitus, maldigestion, and pediatrics. It also includes blood volume replacement and liver and renal insufficiency.
Ipsen SA (Ipsen) is a multinational specialty biopharmaceutical firm that produces and distributes pharmaceuticals to treat neurological disorders, rare diseases, and cancer. The business creates and markets cutting-edge medications for cancer, neurological disorders, and uncommon diseases. It also provides treatments for gastrointestinal problems and neurodegenerative pathologies. In a few countries, Ipsen offers its medications directly to hospitals and through a network of wholesalers.
Key Companies in the somatostatin analogs market include
-
Novartis AG (Switzerland)
-
Ipsen Pharma (France)
-
Fresenius Kabi (Germany)
-
Peptron (South Korea)
-
Pfizer Inc. (US)
-
Teva Pharmaceuticals Inc. (Israel)
Somatostatin Analogs Industry Developments
August 2021:For $330 million, the UK-based specialty pharmaceutical firm Amryt Pharma plc purchased Chiasma, Inc. With a considerable commercial possibility, this acquisition increases the potential of Mycapssa in patients with carcinoid symptoms caused by neuroendocrine tumors ('NET'). Acromegaly and hormonal abnormalities are treated using pharmaceuticals created by the US-based biopharmaceutical business Chiasma Inc.
Somatostatin Analogs Market Segmentation
Somatostatin Analogs Type Outlook (USD Billion, 2018-2032)
-
Octreotide
-
Lanreotide
-
Pasireotide
Somatostatin Analogs Application Outlook (USD Billion, 2018-2032)
-
Neuroendocrine Tumor (NET)
-
Acromegaly
-
Others
Somatostatin Analogs Regional Outlook (USD Billion, 2018-2032)
-
North America
-
US
-
Canada
-
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
-
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
